SART1 antibody [N2C1], Internal

GeneTex

SART1 antibody [N2C1], Internal

9

WB: 1:1000-1:10000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

ImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Polyclonal

0.76 mg/ml

Unconjugated

SART1

spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP

Ara1; HAF; HOMS1; hSART-1; hSnu66; hypoxia associated factor; IgE autoantigen; SART-1; SART1(259) protein; SART1(800) protein; SART1, U4/U6.U5 tri-snRNP-associated protein 1; SART1259; small nuclear ribonucleoprotein 110kDa (U4/U6.U5); SNRNP110; Snu66; SNU66 homolog; squamous cell carcinoma antigen recognised by T cells; squamous cell carcinoma antigen recognized by T-cells 1; U4/U6.U5 tri-snRNP-associated 110 kDa protein; U4/U6.U5 tri-snRNP-associated protein 1

Rabbit

IgG

U4/U6.U5 tri-snRNP-associated protein 1

This gene encodes two proteins, the SART1(800) protein expressed in the nucleus of the majority of proliferating cells, and the SART1(259) protein expressed in the cytosol of epithelial cancers. The SART1(259) protein is translated by the mechanism of -1 frameshifting during posttranscriptional regulation; its full-length sequence is not published yet. The two encoded proteins are thought to be involved in the regulation of proliferation. Both proteins have tumor-rejection antigens. The SART1(259) protein possesses tumor epitopes capable of inducing HLA-A2402-restricted cytotoxic T lymphocytes in cancer patients. This SART1(259) antigen may be useful in specific immunotherapy for cancer patients and may serve as a paradigmatic tool for the diagnosis and treatment of patients with atopy. The SART1(259) protein is found to be essential for the recruitment of the tri-snRNP to the pre-spliceosome in the spliceosome assembly pathway. [provided by RefSeq]

Human, Mouse

-20°C or -80°C,2°C to 8°C

12352203